Edward Kaye

Dr. Edward M.
Kaye, MD, is a Chief Executive Officer & Director at Aurora Therapeutics, Inc., an Independent Director at Cytokinetics, Inc. and an Advisory Board Member at CureDuchenne Ventures LLC.
He is on the Board of Directors at Aurora Therapeutics, Inc., Stoke Therapeutics, Inc., Cytokinetics, Inc., Massachusetts Biotechnology Council and Convergence Bio, Inc. Dr. Kaye was previously employed as an Independent Director by Avidity Biosciences, Inc., an Independent Director by NeuroVia, Inc., a Group VP-Medical Affairs & Clinical Development by Genzyme Corp., a Chief-Biochemical Genetics by The Children's Hospital of Philadelphia, a Chief-Neurology by St. Christopher's Hospital for Children LLC, and an Associate Professor by Perelman School of Medicine.
He also served on the board at Sarepta Therapeutics, Inc. He received his undergraduate degree from Loyola University New Orleans and a doctorate degree from Stritch School of Medicine.